03.07.2012 • News

BASF Sells Marine Biopolymers Business to Seagarden

BASF and the Norwegian company Seagarden signed a contract to transfer the Chitosan marine biopolymers business. Chitosan marine biopolymers are used in personal care products and as pharmaceutical ingredients. The transaction is expected to be formally completed by August 2012.

The divestment of the Chitosan business from former Cognis results from the portfolio optimization following the acquisition of Cognis by BASF in 2010. The Chitosan business including the production site in Tromsoe, Norway, will be owned by the Norwegian specialist for natural seafood ingredients, marine bioactives and biopolymers, Seagarden through its subsidiary Chitinor. The customers have been informed accordingly and conditions have been fixed to ensure supply reliability through the transition.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.